Strides Pharma Global Pte. Singapore, a step‐down wholly owned subsidiary, has received approval for Lidocaine Ointment USP 5% from the USFDA.
Share price of Strides Pharma Science gained 3.2 percent in the early trade on Thursday after it received approval for Lidocaine Ointment from
the United States Food & Drug Administration (USFDA).
Strides Pharma Global Pte. Singapore, a step‐down wholly owned subsidiary, has received approval for Lidocaine Ointment USP 5% from the
USFDA.
Lidocaine Ointment is a generic version of Xylocaine Ointment of AstraZeneca Pharmaceuticals LP.
The product will be marketed by Strides Pharma Inc. in the US market and will be launched immediately.
The company has 80 cumulative ANDA filings with USFDA of which 54 ANDAs have been approved as of date and 26 are pending approval.
At 09:24 hrs Strides Pharma Science was quoting at Rs 474, up Rs 10.70, or 2.31 percent on the BSE.
WhatsApp us
Pingback: 마사지
Pingback: 메이저바카라
Pingback: 카지노사이트
Pingback: كلمات
Pingback: order lortab online in usa canada uk australia without prescription nextday shipping
Pingback: 메이저놀이터
Pingback: Coolsculpting
Pingback: michele watches replica cheap
Pingback: watchestend.com
Pingback: replique rolex
Pingback: Ashly MX-406 manuals
Pingback: it danışmanlığı
Pingback: anti screenshot
Pingback: Unlimited Web Hosting from $0.99
Pingback: buy mdma molly ecstasy
Pingback: comprare follower italiani spotify
Pingback: sell cvv dumps
Pingback: 테니스 예능 핫테TV
Pingback: sbobet
Pingback: Buy Guns Online
Pingback: sbo
Pingback: 토토사이트
Pingback: Aller voir
Pingback: Ammunition for sale online
Pingback: แจกเครดิตฟรี
Pingback: บาร์โฮส
Pingback: web
Pingback: go x san francisco